EMA Authorised: Iressa (gefitinib) — AstraZeneca AB

View source ↗

Summary

Iressa (gefitinib) is authorised in the EU for non-small cell lung carcinoma (carcinoma, non-small-cell lung).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Iressa (gefitinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: AstraZeneca AB. Decision date: 14/07/2023